Skip to Content
Søk Menu
We cover

ASCO GU | Genitourinary Cancers Symposium

ASCO GU 2025

Neeraj Agarwal

Talazoparib and Enzalutamide: A Game-Changer for mCRPC

/ Neeraj Agarwal
ASCOGU25Prostatakreft Play the Video

ASCO GI 2025

We met leading experts
Get their insight into current studies and new knowledge in oncology

Access full coverage

ASCO GU 2025

Real-World Treatment Patterns of Nivolumab + Cabozantinib Compared with Other 1L IO Combinations in mRCC

/ Cherrishe Brown-Bickerstaff / Jan Andreasen
ASCOGU25Nyrekreft
Thomas Powles

Bladder Cancer Treatment Advancements: Key Findings and Progress

/ Thomas Powles
ASCOGU25Blærekreft Play the Video

Bone Pain as a Key Prognostic Indicator in Castration-Sensitive Prostate Cancer

/ Deniz Tural / Jan Andreasen
ASCOGU25Prostatakreft

Real-Life Data Confirms Avelumab Maintenance Benefits in Metastatic Urothelial Carcinoma

/ Deniz Tural / Jan Andreasen
ASCOGU25Blærekreft

Cabozantinib Real-World Effectiveness in the Second-Line Setting of Metastatic Renal Cell Carcinoma

/ Martin Zarba / Jan Andreasen
ASCOGU25Nyrekreft
Philippe Barthélémy

Real World Longer-Term Follow-Up Data Confirms the Effectiveness and Safety of Avelumab 1st Line Maintenance Treatment of Low-Burden Urothelial Cancer

/ Philippe Barthelemy
ASCOGU25 Play the Video

Danish Study Reveals Doubling of Kidney Cancer Cases and a Growing Gender Gap 

/ Johanne Ahrenfeldt / Jan Andreasen
ASCOGU25Nyrekreft
Petros Grivas

Bladder Cancer: Avelumab Maintenance Shows Benefit for Both Patients With and Without Diabetes Mellitus

/ Petros Grivas
ASCOGU25BlærekreftType 2-diabetes Play the Video
Peter J. Goebell

Real-World Effectiveness of Avelumab in First-Line Maintenance for Bladder Cancer

/ Peter J. Goebell
ASCOGU25Blærekreft Play the Video
Nick James

Oestrogen Reimagined: A Breakthrough Approach for Metastatic Prostate Cancer

/ Nick James
ASCOGU25Prostatakreft Play the Video

ASCO 2025: Groundbreaking Data in Bladder and Prostate Cancers

/ Jan Andreasen
ASCOGU25 Play the Video
Helen Moon

Influence of Tumor Burden on Treatment Strategies and Clinical Outcomes in LA/mUC Patients Receiving Avelumab First-Line Maintenance: Insights from Real-World Data

/ Helen Moon
ASCOGU25Blærekreft Play the Video
Sylvie Negrier

Cabozantinib Shows Promising Results in Treatment of Patients with Non-Locally Pretreated Brain Metastases from Renal Cell Carcinoma

/ Sylvie Negrier
ASCOGU25Nyrekreft Play the Video

LBA 18: Improvement in Survival with the Addition of Talazoparib to First-Line Enzalutamide Treatment in RR-Deficient mCRPC Patients

/ Jan Andreasen
ASCOGU25

Abstracts fra ASCO GU 2024

ASCO GU 2024: CheckMate 914 Trial – Adjuvant Nivolumab Monotherapy vs Placebo for Localized Renal Cell Carcinoma at High Risk of Relapse After Nephrectomy

/ Onkologi / Sofie Pohl

ASCO GU 2024: A Combination of Cabozantinib and Atezolizumab is Promising for Advanced Prostate Cancer Patients with Poor Prognoses

/ Onkologi / Sofie Pohl

ASCO GU 2024: Updated Results from AVENANCE – Real-World Effectiveness of Avelumab in Patients with Advanced Urothelial Carcinoma

/ Onkologi / Sofie Pohl

The 2024 ASCO Genitourinary Cancers Symposium Will Be Covered by BestPractice Nordic

/ Onkologi / Sofie Pohl

The 2024 ASCO Genitourinary Cancers Symposium Will Be Covered by BestPractice Nordic

/ Sofie Pohl
ASCOGU24Gynekologisk kreft

MEDtalks fra ASCO GU 2024

Marc Eid og Karl Semaan

Cancer Epigenomics Improve the Overall Survival and the Quality of Life

/ Marc Eid / Karl Semaan
ASCOGU24Prostatakreft Play the Video
Wadih Issa

Comparing Downstaging in RCC-Patients with Tumor or Without Tumor Thrombus Receiving Neoadjuvant ICI Regimen

/ Wadih Issa
ASCOGU24Nyrekreft Play the Video
Eddy Saad

Understanding Mechanisms Behind Acquired Resistance to Immunotherapy in Metastatic Renal Cell Carcinoma

/ Eddy Saad
ASCOGU24Nyrekreft Play the Video
Renee Maria Saliby

The Potential for Intermediate Clinical Endpoints as Surrogates for Overall Survival

/ Renee Maria Saliby
ASCOGU24Nyrekreft Play the Video
Philipp Ivanyi

Real-World Evidence on Lenvatinib plus Everolimus in Patients with Pre-Treated Advanced Renal Cell Carcinoma

/ Philipp Ivanyi
ASCOGU24Nyrekreft Play the Video
Ahmed Rehan

Real-World Data on Maintenance Avelumab Treatment

/ Ahmed Rehan
ASCOGU24Blærekreft Play the Video
Petros Grivas

Long-Term Patient-Reported Outcomes Data from the JAVELIN Bladder 100 Trial in Patients with Advanced Urothelial Carcinoma

/ Petros Grivas
ASCOGU24Blærekreft Play the Video
Andrea Apolo

Results from Study of Pembrolizumab in Muscle-Invasive and Locally Advanced Urothelial Carcinoma

/ Andrea Apolo
ASCOGU24Blærekreft Play the Video
Thomas Powles

Patient-Reported Outcomes of Belzutifan versus Everolimus in Patients with Previously Treated Advanced Renal Cell Carcinoma

/ Thomas Powles
ASCOGU24Nyrekreft Play the Video
Load more

A Long-Term Benefit of Darolutamide for Patients with nmCRPC

/ Onkologi / Neal Shore

Enfortumab Vedotin as Neoadjuvant Treatment for MIBC

/ Onkologi / Daniel Petrylak

Inverse Correlation between Natural Killer Cell and Treatment with Enzalutamide

/ Onkologi / Ahmed H. Zedan

CAPItello-280 Trial Aims to Confirm Findings from ProCAID Trial

/ Onkologi / Simon Crabb

IMvigor130: Final overall survival (OS) analysis of atezolizumab with/without chemotherapy

/ Onkologi / Aristotle Bamias

Uro Oncology 2023 • Meet the experts

Få tilgang

ASCO GU 2022

Bone mineral density in patients with castration-sensitive prostate cancer treated with abiraterone

/ Guilhem Roubaud
ASCOGU22Prostatakreft Play the Video
Kim Nguyen Chi

New potential first-line therapy for patients with mCR-prostate cancer and HRR-alterations

/ Kim Nguyen Chi
ASCOGU22Prostatakreft Play the Video
Redas Trepiakas

CYCLONE 2: Abiraterone acetate plus prednisone with or without abemaciclib in patients with metastatic castration-resistant prostate cancer

/ Redas Trepiakas
ASCOGU22Prostatakreft Play the Video
Daniel P. Petrylak

Promising neoadjuvant antitumor activity for patients with muscle-invasive bladder cancer

/ Daniel P. Petrylak
ASCOGU22Blærekreft Play the Video

Novel intra-vesical drug delivery system, TAR-200, to be assessed in patients with high-risk non-muscle-invasive bladder cancer

/ BestPractice Nordic
ASCOGU22Blærekreft
Simon Crabb

Maintenance PARP inhibition following chemotherapy for metastatic urothelial carcinoma

/ Simon Crabb
ASCOGU22Blærekreft Play the Video
Load more

Innhold fra tidligere dekning

Management of Erdafitinib, a pan-FGFR kinase inhibitor, treatment-emergent adverse events

/ Arlene O. Siefker-Radtke
ASCOGU21Blærekreft Play the Video

Patient-reported outcomes of patients with advanced renal cell carcinoma treated with first-line nivolumab plus cabozantinib

/ David Cella
ASCOGU21Nyrekreft Play the Video

Comorbidity leads to poorer survival in patients with renal cell carcinoma in Danish cohort study

/ BestPractice Nordic
ASCOGU21Nyrekreft

Final analysis of TITAN confirms survival benefit of apalutamide for metastatic castration-sensitive prostate cancer

/ BestPractice Nordic
ASCOGU21Prostatakreft
Mere indhold fra ASCO 2021

Back to top